---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-035380"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:05:30.730369+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports FY2022 net loss of $29.9M; cash runs into Q3 2023; suspends frank relapse enrollment

## Summary
- Net loss $29.9M for FY2022, improved from $41.9M in prior year.
- Cash and cash equivalents $11.8M at Dec 31, 2022; expected to fund operations into Q3 2023.
- Suspended enrollment of frank relapse patients in ARTEMIS trial after no objective responses; re-evaluating modifications.
- MT-401 showed MRD+ responses: one patient bridged to transplant, another with 70% PCR reduction; data expected H2 2023.
- Wilson Wolf services agreement provided $8M upfront; Lincoln Park equity facility for up to $25M.

## SEC filing metadata
- accession: 0001104659-23-035380
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923035380/0001104659-23-035380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923035380/tm239491d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-035380
- JSON: https://secwatch.observer/filing/0001104659-23-035380.json
- Plain text: https://secwatch.observer/filing/0001104659-23-035380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.